Gregory R. Mundy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gregory R. Mundy has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
B F Boyce
5 shared publicationsT A Guise
3 shared publicationsT Yoneda
3 shared publicationsDi Chen
School of Medicine and Dentistry, Department of Orthopaedics, University of Rochester, Rochester, NY 14642, USA
2 shared publicationsMing Zhao
Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, 78229, USA
2 shared publicationsA J Yates
1 shared publication
Latest Publications
- Open Access
- 1 February 2006
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 83 (2) , 427S-430S
Nutritional modulators of bone remodeling during aging
Bone mass declines progressively with age in both men and women from the age of ≈30 y. Increased longevity will inevitability be associated with an increase in the incidence of osteoporosis, its associated complications, and incurred health care costs. Current pharmacologic approaches focus on inhibiting bone resorption in those with osteoporosis but do little to improve bone mass. Increased understanding of the cellular events responsible for normal bone formation has led to multiple pathways that can be targeted to positively influence bone mass. Bone morphogenetic proteins (BMPs) have been shown to stimulate bone formation, and the BMP2 gene was recently linked to osteoporosis. BMP-2 therefore represents one potential molecular target to identify new agents to simulate bone formation. Research is accumulating on the positive effects of dietary sources that stimulate the BMP2 promoter and their effects on bone formation. Flavonoids and statins occur naturally in food products and have been shown to promote bone formation. It may be possible to influence peak bone mass by dietary means and to decrease the risk of osteoporosis in later life. To ease the future burden of osteoporosis, focusing on prevention will be key, and this could include dietary interventions to stimulate bone formation.
- 1 February 2006
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 83 (2) , 427S-430S
Open AccessNutritional modulators of bone remodeling during aging
Bone mass declines progressively with age in both men and women from the age of ≈30 y. Increased longevity will inevitability be associated with an increase in the incidence of osteoporosis, its associated complications, and incurred health care costs. Current pharmacologic approaches focus on inhibiting bone resorption in those with osteoporosis but do little to improve bone mass. Increased understanding of the cellular events responsible for normal bone formation has led to multiple pathways that can be targeted to positively influence bone mass. Bone morphogenetic proteins (BMPs) have been shown to stimulate bone formation, and the BMP2 gene was recently linked to osteoporosis. BMP-2 therefore represents one potential molecular target to identify new agents to simulate bone formation. Research is accumulating on the positive effects of dietary sources that stimulate the BMP2 promoter and their effects on bone formation. Flavonoids and statins occur naturally in food products and have been shown to promote bone formation. It may be possible to influence peak bone mass by dietary means and to decrease the risk of osteoporosis in later life. To ease the future burden of osteoporosis, focusing on prevention will be key, and this could include dietary interventions to stimulate bone formation.
- 1 May 2005
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (5) , 242-243
How can bone turnover markers be best utilized for prediction of skeletal events in patients with solid tumors?
- 1 May 2005
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (5) , 242-243
How can bone turnover markers be best utilized for prediction of skeletal events in patients with solid tumors?
- Top Cited Papers
- 1 December 2004
- Published by Taylor & Francis in Growth Factors
- Vol. 22 (4) , 233-241
Bone Morphogenetic Proteins
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the transforming growth factor β (TGFβ) superfamily. The roles of BMPs in embryonic development and cellular functions in postnatal and adult animals have been extensively studied in recent years. Signal transduction studies have revealed that Smad1, 5 and 8 are the immediate downstream molecules of BMP receptors and play a central role in BMP signal transduction. Studies from transgenic and knockout mice and from animals and humans with naturally occurring mutations in BMPs and related genes have shown that BMP signaling plays critical roles in heart, neural and cartilage development. BMPs also play an important role in postnatal bone formation. BMP activities are regulated at different molecular levels. Preclinical and clinical studies have shown that BMP-2 can be utilized in various therapeutic interventions such as bone defects, non-union fractures, spinal fusion, osteoporosis and root canal surgery. Tissue-specific knockout of a specific BMP ligand, a subtype of BMP receptors or a specific signaling molecule is required to further determine the specific role of a BMP ligand, receptor or signaling molecule in a particular tissue. BMPs are members of the TGFβ superfamily. The activity of BMPs was first identified in the 1960s (Urist, M.R. (1965) “Bone formation by autoinduction”, Science 150, 893–899), but the proteins responsible for bone induction remained unknown until the purification and sequence of bovine BMP-3 (osteogenin) and cloning of human BMP-2 and 4 in the late 1980s (Wozney, J.M. et al. (1988) “Novel regulators of bone formation: molecular clones and activities”, Science 242, 1528–1534; Luyten, F.P. et al. (1989) “Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation”, J. Biol. Chem. 264, 13377–13380; Wozney, J.M. (1992) “The bone morphogenetic protein family and osteogenesis”, Mol. Reprod. Dev. 32, 160–167). To date, around 20 BMP family members have been identified and characterized. BMPs signal through serine/threonine kinase receptors, composed of type I and II subtypes. Three type I receptors have been shown to bind BMP ligands, type IA and IB BMP receptors (BMPR-IA or ALK-3 and BMPR-IB or ALK-6) and type IA activin receptor (ActR-IA or ALK-2) (Koenig, B.B. et al. (1994) “Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells”, Mol. Cell. Biol. 14, 5961–5974; ten Dijke, P. et al. (1994) “Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4”, J. Biol. Chem. 269, 16985–16988; Macias-Silva, M. et al. (1998) “Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2”, J. Biol. Chem. 273, 25628–25636). Three type II receptors for BMPs have also been identified and they are type II BMP receptor (BMPR-II) and type II and IIB activin receptors (ActR-II and ActR-IIB) (Yamashita, H. et al. (1995) “Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects”, J. Cell. Biol. 130, 217–226; Rosenzweig, B.L. et al. (1995) “Cloning and characterization of a human type II receptor for bone morphogenetic proteins”, Proc. Natl Acad. Sci. USA 92, 7632–7636; Kawabata, M. et al. (1995) “Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-β receptor”, J. Biol. Chem. 270, 5625–5630). Whereas BMPR-IA, IB and II are specific to BMPs, ActR-IA, II and IIB are also signaling receptors for activins. These receptors are expressed differentially in various tissues. Type I and II BMP receptors are both indispensable for signal transduction. After ligand binding they form a heterotetrameric-activated receptor complex consisting of two pairs of a type I and II receptor complex (Moustakas, A. and C.H. Heldi (2002) “From mono- to oligo-Smads: the heart of the matter in TGFβ signal transduction” Genes Dev. 16, 67–871). The type I BMP receptor substrates include a protein family, the Smad proteins, that play a central role in relaying the BMP signal from the receptor to target genes in the nucleus. Smad1, 5 and 8 are phosphorylated by BMP receptors in a ligand-dependent manner (Hoodless, P.A. et al. (1996) “MADR1, a MAD-related protein that functions in BMP2 signaling pathways”, Cell 85, 489–500; Chen Y. et al. (1997) “Smad8 mediates the signaling of the receptor serine kinase”, Proc. Natl Acad. Sci. USA 94, 12938–12943; Nishimura R. et al. (1998) “Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12”, J. Biol. Chem. 273, 1872–1879). After release from the receptor, the phosphorylated Smad proteins associate with the related protein Smad4, which acts as a shared partner. This complex translocates into the nucleus and participates in gene transcription with other transcription factors (Fig. 1). A significant advancement about the understanding of in vivo functions of BMP ligands, receptors and signaling molecules has been achieved in recent years.
- 1 December 2004
- Published by Taylor & Francis in Growth Factors
- Vol. 22 (4) , 233-241
Top Cited PapersBone Morphogenetic Proteins
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the transforming growth factor β (TGFβ) superfamily. The roles of BMPs in embryonic development and cellular functions in postnatal and adult animals have been extensively studied in recent years. Signal transduction studies have revealed that Smad1, 5 and 8 are the immediate downstream molecules of BMP receptors and play a central role in BMP signal transduction. Studies from transgenic and knockout mice and from animals and humans with naturally occurring mutations in BMPs and related genes have shown that BMP signaling plays critical roles in heart, neural and cartilage development. BMPs also play an important role in postnatal bone formation. BMP activities are regulated at different molecular levels. Preclinical and clinical studies have shown that BMP-2 can be utilized in various therapeutic interventions such as bone defects, non-union fractures, spinal fusion, osteoporosis and root canal surgery. Tissue-specific knockout of a specific BMP ligand, a subtype of BMP receptors or a specific signaling molecule is required to further determine the specific role of a BMP ligand, receptor or signaling molecule in a particular tissue. BMPs are members of the TGFβ superfamily. The activity of BMPs was first identified in the 1960s (Urist, M.R. (1965) “Bone formation by autoinduction”, Science 150, 893–899), but the proteins responsible for bone induction remained unknown until the purification and sequence of bovine BMP-3 (osteogenin) and cloning of human BMP-2 and 4 in the late 1980s (Wozney, J.M. et al. (1988) “Novel regulators of bone formation: molecular clones and activities”, Science 242, 1528–1534; Luyten, F.P. et al. (1989) “Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation”, J. Biol. Chem. 264, 13377–13380; Wozney, J.M. (1992) “The bone morphogenetic protein family and osteogenesis”, Mol. Reprod. Dev. 32, 160–167). To date, around 20 BMP family members have been identified and characterized. BMPs signal through serine/threonine kinase receptors, composed of type I and II subtypes. Three type I receptors have been shown to bind BMP ligands, type IA and IB BMP receptors (BMPR-IA or ALK-3 and BMPR-IB or ALK-6) and type IA activin receptor (ActR-IA or ALK-2) (Koenig, B.B. et al. (1994) “Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells”, Mol. Cell. Biol. 14, 5961–5974; ten Dijke, P. et al. (1994) “Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4”, J. Biol. Chem. 269, 16985–16988; Macias-Silva, M. et al. (1998) “Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2”, J. Biol. Chem. 273, 25628–25636). Three type II receptors for BMPs have also been identified and they are type II BMP receptor (BMPR-II) and type II and IIB activin receptors (ActR-II and ActR-IIB) (Yamashita, H. et al. (1995) “Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects”, J. Cell. Biol. 130, 217–226; Rosenzweig, B.L. et al. (1995) “Cloning and characterization of a human type II receptor for bone morphogenetic proteins”, Proc. Natl Acad. Sci. USA 92, 7632–7636; Kawabata, M. et al. (1995) “Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-β receptor”, J. Biol. Chem. 270, 5625–5630). Whereas BMPR-IA, IB and II are specific to BMPs, ActR-IA, II and IIB are also signaling receptors for activins. These receptors are expressed differentially in various tissues. Type I and II BMP receptors are both indispensable for signal transduction. After ligand binding they form a heterotetrameric-activated receptor complex consisting of two pairs of a type I and II receptor complex (Moustakas, A. and C.H. Heldi (2002) “From mono- to oligo-Smads: the heart of the matter in TGFβ signal transduction” Genes Dev. 16, 67–871). The type I BMP receptor substrates include a protein family, the Smad proteins, that play a central role in relaying the BMP signal from the receptor to target genes in the nucleus. Smad1, 5 and 8 are phosphorylated by BMP receptors in a ligand-dependent manner (Hoodless, P.A. et al. (1996) “MADR1, a MAD-related protein that functions in BMP2 signaling pathways”, Cell 85, 489–500; Chen Y. et al. (1997) “Smad8 mediates the signaling of the receptor serine kinase”, Proc. Natl Acad. Sci. USA 94, 12938–12943; Nishimura R. et al. (1998) “Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12”, J. Biol. Chem. 273, 1872–1879). After release from the receptor, the phosphorylated Smad proteins associate with the related protein Smad4, which acts as a shared partner. This complex translocates into the nucleus and participates in gene transcription with other transcription factors (Fig. 1). A significant advancement about the understanding of in vivo functions of BMP ligands, receptors and signaling molecules has been achieved in recent years.
- 8 September 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (19) , 10588-10589
Endothelin-1 and osteoblastic metastasis
- 8 September 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (19) , 10588-10589
Endothelin-1 and osteoblastic metastasis
- Open Access
Mechanisms of osteolytic bone metastases in breast carcinoma
Osteolytic and osteoblastic metastases are often the cause of considerable morbidity in patients with advanced prostate and breast carcinoma. Breast carcinoma metastasis to bone occurs because bone provides a favorable site for aggressive behavior of metastatic cancer cells. A vicious cycle arises between cancer cells and the bone microenvironment, which is mediated by the production of growth factors such as transforming growth factor β and insulin growth factor from bone and parathyroid hormone‐related protein (PTHrP) produced by tumor cells. Osteolysis and tumor cell accumulation can be interrupted by inhibiting any of these limbs of the vicious cycle. For example, bisphosphonates (e.g., pamidronate, ibandronate, risedronate, clodronate, and zoledronate) inhibit both bone lesions and tumor cell burden in bone in experimental models of breast carcinomametastasis. Neutralizing antibodies to PTHrP, which inhibit PTHrP effects on osteoclastic bone resorption, also reduce osteolytic bone lesions and tumor burden in bone. Other pharmacologic approaches to inhibit PTHrP produced by breast carcinoma cells in the bone microenvironment also produce similar beneficial effects. Identification of the molecular mechanisms responsible for osteolytic metastases is crucial in designing effective therapy for this devastating complication. Cancer 2003;97(3 Suppl):834–9. © 2003 American Cancer Society. DOI 10.1002/cncr.11132
Open AccessMechanisms of osteolytic bone metastases in breast carcinoma
Osteolytic and osteoblastic metastases are often the cause of considerable morbidity in patients with advanced prostate and breast carcinoma. Breast carcinoma metastasis to bone occurs because bone provides a favorable site for aggressive behavior of metastatic cancer cells. A vicious cycle arises between cancer cells and the bone microenvironment, which is mediated by the production of growth factors such as transforming growth factor β and insulin growth factor from bone and parathyroid hormone‐related protein (PTHrP) produced by tumor cells. Osteolysis and tumor cell accumulation can be interrupted by inhibiting any of these limbs of the vicious cycle. For example, bisphosphonates (e.g., pamidronate, ibandronate, risedronate, clodronate, and zoledronate) inhibit both bone lesions and tumor cell burden in bone in experimental models of breast carcinomametastasis. Neutralizing antibodies to PTHrP, which inhibit PTHrP effects on osteoclastic bone resorption, also reduce osteolytic bone lesions and tumor burden in bone. Other pharmacologic approaches to inhibit PTHrP produced by breast carcinoma cells in the bone microenvironment also produce similar beneficial effects. Identification of the molecular mechanisms responsible for osteolytic metastases is crucial in designing effective therapy for this devastating complication. Cancer 2003;97(3 Suppl):834–9. © 2003 American Cancer Society. DOI 10.1002/cncr.11132
- Top Cited Papers
- 1 August 2002
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 2 (8) , 584-593
Metastasis to bone: causes, consequences and therapeutic opportunities
Common tumours, such as those of the breast, lung and prostate, frequently metastasize to bone, and in many patients with advanced disease the skeleton is the site of the most significant tumour burden. There are different patterns of bone effects in patients with cancer, ranging from purely or mostly destructive or osteolytic (breast cancer, myeloma), to mostly bone-forming or osteoblastic (prostate cancer). In the case of breast-cancer-causing osteolysis, the main mediator is parathyroid-hormone-related peptide (PTHrP), whereas, in osteoblastic lesions, known mediators include endothelin-1 and platelet-derived growth factor. In osteolytic metastasis, there is a 'vicious cycle' in the bone microenvironment, whereby bi-directional interactions between tumour cells and osteoclasts lead to both osteolysis and tumour growth. The molecular mechanisms that are responsible for this vicious cycle are now being clarified and involve tumour-cell production of PTHrP and bone-derived growth factors that are released as a consequence of increased bone resorption. Bisphosphonates interrupt the vicious cycle and cause not only a reduction in osteolytic bone lesions, but also decrease the tumour burden in bone. More-effective treatments for interruption of the vicious cycle are now being developed, including specifically neutralizing antibodies to PTHrP and more efficacious osteoclast inhibitors.
- 1 August 2002
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 2 (8) , 584-593
Top Cited PapersMetastasis to bone: causes, consequences and therapeutic opportunities
Common tumours, such as those of the breast, lung and prostate, frequently metastasize to bone, and in many patients with advanced disease the skeleton is the site of the most significant tumour burden. There are different patterns of bone effects in patients with cancer, ranging from purely or mostly destructive or osteolytic (breast cancer, myeloma), to mostly bone-forming or osteoblastic (prostate cancer). In the case of breast-cancer-causing osteolysis, the main mediator is parathyroid-hormone-related peptide (PTHrP), whereas, in osteoblastic lesions, known mediators include endothelin-1 and platelet-derived growth factor. In osteolytic metastasis, there is a 'vicious cycle' in the bone microenvironment, whereby bi-directional interactions between tumour cells and osteoclasts lead to both osteolysis and tumour growth. The molecular mechanisms that are responsible for this vicious cycle are now being clarified and involve tumour-cell production of PTHrP and bone-derived growth factors that are released as a consequence of increased bone resorption. Bisphosphonates interrupt the vicious cycle and cause not only a reduction in osteolytic bone lesions, but also decrease the tumour burden in bone. More-effective treatments for interruption of the vicious cycle are now being developed, including specifically neutralizing antibodies to PTHrP and more efficacious osteoclast inhibitors.
- 1 February 2002
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 53 (1) , 337-354
Directions of Drug Discovery in Osteoporosis
▪ Abstract Osteoporosis is a condition of increasing importance and prevalence in all parts of the world and particularly in Asia. Recent advances have led to the introduction of effective drugs that decrease bone resorption and stabilize bone mass. However, these drugs have been identified by serendipity rather than rational drug design and are not ideal because of limited bioavailability, mode of administration, or other unwanted effects. There is still a place for even more suitable and effective resorption inhibitors than those currently available. The more compelling need in this field is an acceptable drug that is anabolic for bone, that safely and acceptably increases bone mass and improves the disturbances in bone microarchitecture that characterize established and advanced osteoporosis. Possible approaches to identifying more effective resorption inhibitors and new anabolic agents are discussed.
- 1 February 2002
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 53 (1) , 337-354
Directions of Drug Discovery in Osteoporosis
▪ Abstract Osteoporosis is a condition of increasing importance and prevalence in all parts of the world and particularly in Asia. Recent advances have led to the introduction of effective drugs that decrease bone resorption and stabilize bone mass. However, these drugs have been identified by serendipity rather than rational drug design and are not ideal because of limited bioavailability, mode of administration, or other unwanted effects. There is still a place for even more suitable and effective resorption inhibitors than those currently available. The more compelling need in this field is an acceptable drug that is anabolic for bone, that safely and acceptably increases bone mass and improves the disturbances in bone microarchitecture that characterize established and advanced osteoporosis. Possible approaches to identifying more effective resorption inhibitors and new anabolic agents are discussed.
- 1 January 2001
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 2 (1) , 105-115
Growth Regulatory Factors and Bone
- 1 January 2001
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 2 (1) , 105-115
Growth Regulatory Factors and Bone